Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLS-0071 in steroid-refractory acute graft-versus-host disease
NCT06343792Phase 2Recruiting
- Sponsor
- ReAlta Life Sciences
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Modified Peptides, Native Peptides
- Countries
- 3
01
Overview
A Phase 2 trial of pegtarazimod in Acute Graft-Versus-Host Disease (aGvHD), sponsored by ReAlta Life Sciences. Started Aug 2024; status: recruiting.
02
Drugs
pegtarazimod
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06343792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343792.